pharmaand GmbH drugs

2 results

  • rubraca

    (rucaparib)
    pharmaand GmbH
    Rubraca is indicated for the maintenance treatment of adults with BRCA-mutated recurrent ovarian cancer in response to platinum-based chemotherapy, and for treating BRCA-mutated metastatic castration-resistant prostate cancer after previous treatments. Selection for therapy should be guided by an FDA-approved companion diagnostic.
    Medication Details
    Drug Interactions